TMC Life Sciences BhdXKLS:0101 62 EBITDA Margin % is 15.58% as of Mar. 2026, which is 35% below its 10-year median of 23.97. GuruFocus rates XKLS:0101 with a GF Score™ of 62/100 and a GF Value™ of RM0.62 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 666 Healthcare Providers & Services companies, TMC Life Sciences Bhd ranks better than 67.87% on this metric.
TMC Life Sciences Bhd (XKLS:0101) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
TMC Life Sciences Bhd EBITDA Margin % Related Terms
TMC Life Sciences Bhd EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for TMC Life Sciences Bhd's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XKLS:0101 vs HCA, THC, DVA: EBITDA Margin % Comparison
For the Medical Care Facilities subindustry, TMC Life Sciences Bhd's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TMC Life Sciences Bhd EBITDA Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, TMC Life Sciences Bhd's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where TMC Life Sciences Bhd's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TMC Life Sciences Bhd (XKLS:0101) has a EBITDA Margin % of 15.58% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on TMC Life Sciences Bhd and its competitors. This is 35% below median its historical median of 23.97. Over the past decade, TMC Life Sciences Bhd's EBITDA Margin % has ranged from 14.62 to 27.25. According to the industry distribution chart, TMC Life Sciences Bhd ranks #214 out of 666 companies in the Healthcare Providers & Services industry, placing it in the top 32.1%.
Is TMC Life Sciences Bhd's EBITDA Margin % too high?
TMC Life Sciences Bhd's current EBITDA Margin % of 15.58% is 35% below median its 10-year median of 23.97. Over the past 10 years, this metric has ranged from a low of 14.62 to a high of 27.25. The Healthcare Providers & Services industry median EBITDA Margin % is 10.21. TMC Life Sciences Bhd's value of 15.58% is 52.6% above this industry median. Based on the distribution chart, TMC Life Sciences Bhd ranks #214 out of 666 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, TMC Life Sciences Bhd has a GF Score™ of 62/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does TMC Life Sciences Bhd's EBITDA Margin % compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, TMC Life Sciences Bhd ranks #214 out of 666 companies for EBITDA Margin %. This puts TMC Life Sciences Bhd in the upper half of its industry. The industry median EBITDA Margin % is 10.21. TMC Life Sciences Bhd's value of 15.58% is 52.6% above this benchmark. Historically, TMC Life Sciences Bhd's own EBITDA Margin % has ranged from 14.62 to 27.25 over the past decade. While the company's 10-year median is 23.97 vs. the industry median of 10.21, TMC Life Sciences Bhd has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.21, based on 666 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. TMC Life Sciences Bhd's current EBITDA Margin % of 15.58% is 52.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on TMC Life Sciences Bhd and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TMC Life Sciences Bhd's current EBITDA Margin % is 15.58%, which is 35% below median its own 10-year median of 23.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TMC Life Sciences Bhd stock overvalued right now?
Based on GuruFocus' analysis, TMC Life Sciences Bhd (XKLS:0101) is currently considered Modestly Undervalued. The stock's GF Value™ is RM0.62, compared to a current price of RM0.45 — trading 27.4% below its estimated fair value. The current EBITDA Margin % is 15.58%, which is 35% below median its 10-year median of 23.97 and 52.6% above the Healthcare Providers & Services industry median of 10.21. TMC Life Sciences Bhd's overall GF Score™ is 62/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For TMC Life Sciences Bhd (XKLS:0101), the current EBITDA Margin % is 15.58% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is TMC Life Sciences Bhd (XKLS:0101) Overvalued in 2026?
Based on GuruFocus' analysis, TMC Life Sciences Bhd stock appears to be undervalued.
The current stock price of RM0.45 is trading 27.4% below its estimated GF Value™ of RM0.62.
GuruFocus considers TMC Life Sciences Bhd to be Modestly Undervalued.
Key valuation signals for XKLS:0101:
EBITDA Margin %: 15.58% (35% below median its 10-year median of 23.97)
GF Value™: RM0.62 vs. price of RM0.45 (27.4% below fair value)
Industry Position: 52.6% above the Healthcare Providers & Services median (#214 of 666)
No single metric tells the full story. See the XKLS:0101 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
TMC Life Sciences Bhd is an investment holding company operating a multi-disciplinary tertiary care center and fertility center in Malaysia. It operates Tropicana Medical Centre, Kota Damansara (TMCKD), a medical center located in Petaling Jaya. Its TMCKD provides healthcare services in various medical/surgical specialties and subspecialties, including anesthesiology, cancer, cardiology, colorectal, dermatology, ENT, fertility, gastroenterology, as well as offers internal medicines and respiratory medicines. Its fertility center provides a range of fertility treatments for couples. The company also operates a women's clinic; provides fertility consultancy, laboratory, and embryology services; and offers pharmacy services and products.
62GF Score
Get the complete analysis for XKLS:0101
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XKLS:0101 has been successfully added to your 
